Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450064 | 0.78 | LOXL2 (0.38) | DRD2 | |
| SCHEMBL3511362 | 0.74 | ATM (0.40) | DRD2 | |
| SCHEMBL2455535 | 0.74 | CA12 (0.42) | PNMTPREPHTR2A | |
| SCHEMBL2452820 | 0.74 | MEN1 (0.34) | — | |
| SCHEMBL20536167 | 0.74 | NOTUM (0.32) | DRD2 | |
| SCHEMBL9040112 | 0.71 | DRD2 (0.44) | DRD2 | |
| SCHEMBL7466768 | 0.70 | CSNK2A1 (0.53) | PNMTPDCD1LG2CD274BPTFKAT2B | |
| SCHEMBL388941 | 0.70 | TAAR1 (0.56) | HTR2A | |
| SCHEMBL2458060 | 0.70 | KMT2A (0.33) | DRD2PREP | |
| SCHEMBL3255650 | 0.70 | TAAR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | BROWN ALAN DANIEL | 2010-10-28 | — | — | US | disclosed |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | BROWN ALAN DANIEL | 2010-10-28 | — | — | US | disclosed |
| US-7767715-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767715-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | BROWN ALAN DANIEL | 2009-08-06 | — | — | US | disclosed |
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | BROWN ALAN DANIEL | 2009-08-06 | — | — | US | disclosed |
| US-7528170-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528170-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080267970-A1 | Sulfonamide Derivatives For The Treatment of Diseases | BROWN ALAN DANIEL | 2008-10-30 | — | — | US | disclosed |
| US-20080267970-A1 | Sulfonamide Derivatives For The Treatment of Diseases | BROWN ALAN DANIEL | 2008-10-30 | — | — | US | disclosed |
| EP-1708991-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | SULT2A1, STS, SULT1A1 | PNMT 1833/4885PDCD1LG2 4829/4885CD274 4727/4885 |
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | SULT2A1, STS, SULT1A1 | PNMT 1833/4885PDCD1LG2 4829/4885CD274 4727/4885 |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | LTC4S, LTB4R2, LTB4R | PNMT 1149/4885PDCD1LG2 4075/4885CD274 2949/4885 |
| US-20080267970-A1 | Sulfonamide Derivatives For The Treatment of Diseases | SULT2A1, STS, SULT1A1 | PNMT 1833/4885PDCD1LG2 4829/4885CD274 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.